Molecular comparison of human and mouse pulmonary adenocarcinomas

Experimental Lung Research
A M Malkinson

Abstract

Mice develop lung tumors similar in their histogenesis and molecular features to peripheral adenocarcinomas in humans. The advantage of this model system is that events early in tumorigenesis can be delineated and their biological consequences tested by transgenic and knockout strategies. Both human and murine adenocarcinomas contain Kras mutations; in mice these occur within weeks following carcinogen administration. Decreased expression of similar tumor suppressor genes occur in both species due to mutation, deletion, altered DNA methylation, or unknown mechanisms. These genes include p15, p16, Rb, cyclin D1, p53, Apc, Mcc, and Gjal. Some genes have only been examined in one of these species, such as the deletions in chromosome 3p and the overexpression of bcl 2 in human adenocarcinoma. Not all molecular changes are identical to the two species, however. Quinone oxidoreductase (DT-diaphorase) levels rise in the human tumors but fall in the mouse; the extent of both changes is very dramatic. Similarly, EGF-receptor content often increases in human lung adenocarcinomas but decreases in the mouse tumors. In general, however, the nature of the molecular changes is quite similar.

References

Nov 1, 1991·Cancer·O Auerbach, L Garfinkel
Aug 19, 1991·International Journal of Cancer. Journal International Du Cancer·L G ThaeteD Ross
Jul 17, 1991·Journal of the National Cancer Institute·R J SlebosS Rodenhuis
Oct 1, 1990·The American Journal of Surgical Pathology·R R Miller
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·M YouM W Anderson
Mar 23, 1995·Cancer Letters·R D Cardiff, R J Munn
Aug 2, 1994·Proceedings of the National Academy of Sciences of the United States of America·I E SchauerR A Sclafani
Sep 2, 1993·The New England Journal of Medicine·F PezzellaD Y Mason
Apr 30, 1996·Proceedings of the National Academy of Sciences of the United States of America·S A BelinskyJ P Issa
Jan 1, 1997·Carcinogenesis·S A BelinskyJ Tesfaigzi
Feb 1, 1997·The Journal of Pathology·E A LovejoyD J Harrison
May 23, 1997·Science·L ZhangK W Kinzler
Jul 11, 1998·Experimental Lung Research·R J RuchA M Malkinson

❮ Previous
Next ❯

Citations

Nov 22, 2007·Cancer Chemotherapy and Pharmacology·Laura K ZerbeAlvin M Malkinson
Feb 14, 2009·Pathology Oncology Research : POR·Natália R SalinasValquiria Bueno
Jun 16, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Hildegard M SchullerR Schmoyer
Jun 14, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Hildegard M Schuller, Maria Cekanova
Jun 8, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·A M Malkinson
Apr 12, 2011·Journal of Toxicology and Environmental Health. Part a·Patti C Zeidler-ErdelyJames M Antonini
Oct 30, 2012·Carcinogenesis·Mark Steven MillerMichael T Munley
Dec 8, 2005·Journal of the National Cancer Institute·Alison K BauerSteven R Kleeberger
Jun 2, 2005·Current Opinion in Pulmonary Medicine·Robert L Keith, York E Miller
Mar 17, 2009·American Journal of Physiology. Lung Cellular and Molecular Physiology·Tirumalai RangasamyShyam Biswal
Apr 12, 2013·Oxidative Medicine and Cellular Longevity·Alison K BauerCarla-Maria Alexander
Jul 23, 2004·American Journal of Respiratory Cell and Molecular Biology
Aug 28, 2010·Respiratory Research·Konstantinos DorisGeorgios T Stathopoulos
Nov 1, 2011·PloS One·Alison K BauerSteven R Kleeberger
Aug 5, 2006·Pharmacogenomics·Eric KnocheTimothy A Graubert
Nov 28, 2013·Carcinogenesis·Cezary Jan TredaToshihiro Nukiwa
Nov 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Georgios T StathopoulosTimothy S Blackwell
Jan 3, 2014·Antioxidants & Redox Signaling·Phyllis A Dennery
Mar 15, 2006·Critical Reviews in Clinical Laboratory Sciences·Hellinida Thomadaki, Andreas Scorilas
Apr 15, 2005·Experimental Lung Research·Min WangTheodora R Devereux
Apr 13, 2005·Experimental Lung Research·Debra KrupkeJanan Eppig
May 25, 2010·The Annals of Thoracic Surgery·Johannes R KratzDavid M Jablons
Jan 17, 2009·International Immunopharmacology·Natália Regina Antunes SalinasValquiria Bueno
Jun 21, 2008·Toxicology and Applied Pharmacology·Stephanie T Dance-BarnesMark Steven Miller
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·David C ChristianiKwok Kim
Mar 1, 2006·International Journal of Cancer. Journal International Du Cancer·Cheuk Man HuiAnnie L M Cheung
May 5, 2007·Molecular Carcinogenesis·Katherine A PeeblesAlvin M Malkinson
May 3, 2006·Molecular Carcinogenesis·Jamie E Jennings-GeeMark Steven Miller
Jan 21, 2006·Molecular Nutrition & Food Research·Julie Clark, Ming You
Feb 17, 2006·Molecular Carcinogenesis·Heather S FloydMark Steven Miller
Jul 9, 2004·Toxicology and Applied Pharmacology·Mark Steven Miller
Jul 16, 2015·Stem Cells and Development·Luca PersanoFrancesca Pistollato
Oct 4, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Raphael A Nemenoff, Robert A Winn
Aug 30, 2005·Biochimica Et Biophysica Acta·Klaus-Peter JanssenSylvie Robine

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.